Peer-influenced content. Sources you trust. No registration required. This is HCN.

Clinical Advances in Hematology & OncologyAutologous and Allogeneic CAR T-Cell Therapies: Spotlighting the “Brain-to-Vein” Time

Matthew Lunning, DO, Associate Vice Chair of Research at the University of Nebraska Medical Center, reviews treatment implications of emerging research in CAR T-cell therapy for a variety of lymphomas subtypes, and discusses newer study outcomes, limitations to current CAR-T cell products, the state of allogenic CAR-T cell therapy, and key elements to consider when selecting therapy for a given patient.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form